While treatment strategies for non-small cell lung cancer (NSCLC) has made substantial progress in the past two decades with the advent of molecular targeted agents and immune checkpoint inhibitors, advances in the field of small cell lung cancer (SCLC) have been relatively dismal. The mainstay of treatment for advanced SCLC remains platinum-based doublet chemotherapy in the first line setting, with rechallenge of chemotherapy during relapse for platinum-sensitive disease. In the platinum resistant or refractory settings, there are no standard guidelines for treatment, with various phase II studies showing similar response rates (RR) and survival outcomes for different single agent chemotherapies, including topotecan, irinotecan, taxanes and gemcitabine (1) .
Multiple molecularly targeted agents have been assessed in SCLC with limited success in improving patient outcomes beyond platinum doublet chemotherapy. One of the earliest mechanisms targeted in SCLC was angiogenesis since high vascular endothelial growth factor (VEGF) levels were found to be a poor prognostic marker for SCLC, and preclinical studies supported the use of anti-VEGF agents to improve tumor responses (2) . However, subsequent phase II/III trials undertaken with different anti-VEGF antibodies or small molecule inhibitors were negative, resulting in the discontinuation of anti-VEGF clinical development in SCLC (3). Other signaling pathways have also been assessed in SCLC, including targeted agents against the phosphatidylinostinol 3-kinase (PI3K) pathway and critical apoptotic substrates, such as BCL2. Despite strong evidence of antitumor activity in pre-clinical studies, phase II trials have nevertheless been negative (Figure 1 ) (4).
George and co-workers assessed whole genome sequencing data from 110 SCLC primary tumors, which found that TP53 and RB1 loss were almost universal (100% and 93%, respectively) (5). However, TP53 and RB1 are both notoriously challenging to target and are currently not actionable. Interestingly, inactivating mutations in the Notch family were noted in approximately 25% of SCLC tumors, with Notch activation in LSL-N2ICD mice leading to tumor reduction. The Notch signalling pathway has been shown to be important for the control of neuroendocrine differentiation, and its inhibition may be mediated by DLL3 through ASCL1 (6).
Another promising target, poly(ADP-ribose) polymerase (PARP), has been shown in proteomic profiling studies to be dysregulated in SCLC (7) . There has already been much success in exploiting the concept of synthetic lethality through the inhibition of In addition, evidence has suggested that the dual blockade of PD-1 and CTLA-4 pathways may have synergistic outcomes due to the inhibition of non-redundant mechanisms in immune suppression (14, 15) . Most recently, the CHECKMATE-032 study showed that combination therapy with nivolumab and ipilimumab is more effective than nivolumab monotherapy, with a RR of 23%, mPFS of 3.4 months and 1-year OS of 43% (16) . More importantly, survival curves suggest that there could be a long tail, indicating that some patients are experiencing durable responses; it will be interesting to see if these promising data persist with longer follow up. A phase III study is currently investigating the utility of combined immune checkpoint inhibition as maintenance therapy in patients who achieved at least stable disease after four cycles of standard first line platinum doublet chemotherapy (NCT02538666). Recently, various other drug conjugates including antibody-drug conjugates (ADCs) such as lorvotuzumab mertansine and rovalpituzumab tesirine have been studied in SCLC. Rovalpitizumab tesirine is a humanised anti-delta-like 3 (DLL3) monoclonal antibody conjugated to pyrrolobenzodiazepine (PDB) dimer toxin that binds to a DNA minor groove resulting in DNA damage (23) . It showed a RR of 16% and disease control rate (DCR) of 31% in a phase Ib trial involving patients with relapsed SCLC and large cell neuroendocrine cancer. Looking at the subgroup of patients deemed to be DLL3-positive (tumor DLL3 expression in ≥50% of tumor cells by IHC), the RR and DCR improved to 31% and 85%, respectively (24) . More importantly, antitumor responses were seen in both the platinum sensitive and resistant/refractory settings.
The drug was generally well tolerated, with thrombocytopenia and serosal effusion being the most common grade 3 adverse events. Another ADC that has been assessed in SCLC is lorvotuzumab mertansine, involving a CD56 binding antibody conjugated to a microtubulin inhibitor DM-1. While preclinical and phase I data for lorvotuzumab mertansine appeared promising, the phase II trial investigating its role in combination with carboplatin/etoposide in the first line SCLC setting was discontinued due to a lack of efficacy and possible increased risk of infection and infection-related deaths (25) . Besides the inherent differences in mouse models and human subjects, another possible reason for the high drug attrition rates in late stage SCLC clinical studies could be due to the fact that it has been challenging to recapitulate the multitude of genetic aberrations found in human tumors of SCLC in genetically engineered mouse models (GEMMs) (4) . For example, the complexity of genetic and epigenetic changes brought about by carcinogens in tobacco smoke may not be reflected in these GEMMs, resulting in the simplification of oncogenic pathways involved and an oversight of possible bypass mechanisms employed by tumors to escape cell death.
Nevertheless, in the absence of better animal models, such GEMMs remain the best surrogate for preclinical studies in the current setting.
Many drugs that have been combined with first line therapy with platinum/etoposide treatment have failed to show improved outcomes, likely due to the fact that SCLC is a highly chemosensitive tumor with impressive RR of 70-85% (28), making it challenging to improve such outstanding outcomes without additional significant toxicities. Therefore, rather than combine STA-8666 with chemotherapy in the advanced SCLC setting, STA-8666 should be investigated in a maintenance setting to improve PFS and delay the inevitable relapse seen in patients with SCLC.
Looking to the future, the next steps forward for STA-8666 will be crucial in establishing its niche registration space in an ever expanding armamentarium of novel trial agents that are being assessed along the SCLC treatment pathway.
Ultimately, the challenge now is to determine how best to exploit our improved understanding of the biology of SCLC and the new range of antitumor agents available in the clinic, and to translate them into meaningful management strategies to improve treatment outcomes in this disease of urgent unmet need. 
